middle.news
Why Is Acrux Deferring US Pipeline Investment Despite New Product Launches?
3:50am on Saturday 30th of August, 2025 AEST
•
Pharmaceuticals
Read Story
Why Is Acrux Deferring US Pipeline Investment Despite New Product Launches?
3:50am on Saturday 30th of August, 2025 AEST
Key Points
Revenue down 44% to $4.53 million in FY25
Net loss increased 2% to $5.945 million
Three new topical generic products launched in the US
Licensing agreement secured for Saudi Arabian market
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE